• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pediatr (Rio J) . Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort s

tetano

Editor, Senior Moderator
J Pediatr (Rio J)


. 2020 Nov 9;S0021-7557(20)30225-4.
doi: 10.1016/j.jped.2020.10.008. Online ahead of print.
Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study


Fernanda Lima-Setta[SUP] 1 [/SUP], Maria Clara de Magalh?es-Barbosa[SUP] 2 [/SUP], Gustavo Rodrigues-Santos[SUP] 2 [/SUP], Elaine Augusta das Neves Figueiredo[SUP] 3 [/SUP], Melissa de Lorena Jacques[SUP] 4 [/SUP], Raquel de Seixas Zeitel[SUP] 5 [/SUP], Roberto Sapolnik[SUP] 6 [/SUP], Cibelle Teixeira da Siva Borges[SUP] 7 [/SUP], Vanessa Soares Lanziotti[SUP] 8 [/SUP], Roberta Esteves Vieira de Castro[SUP] 5 [/SUP], Ana Paula Novaes Bellinat[SUP] 9 [/SUP], Thiago Peres da Silva[SUP] 10 [/SUP], Felipe Rezende Caino de Oliveira[SUP] 11 [/SUP], B?rbara Carvalho Santos Dos Reis[SUP] 12 [/SUP], Nat?lia Almeida de Arnaldo Silva Rodriguez Castro[SUP] 13 [/SUP], Jo?o Henrique Garcia Cobas Macedo[SUP] 14 [/SUP], Ana Carolina Cabral Pinheiro Scarlato[SUP] 15 [/SUP], Paula Marins Riveiro[SUP] 16 [/SUP], Isabele Coelho Fonseca da Mota[SUP] 17 [/SUP], Vivian Botelho Lorenzo[SUP] 18 [/SUP], Natalia Martins Lima de Lucena[SUP] 19 [/SUP], Zina Maria Almeida de Azevedo[SUP] 20 [/SUP], Antonio Jos? L A Cunha[SUP] 21 [/SUP], Arnaldo Prata-Barbosa[SUP] 22 [/SUP], Brazilian Research Network in Pediatric Intensive Care (BRnet-PIC)



Affiliations
Free PMC article

Abstract

Objective: To describe the clinical, laboratory, and radiological characteristics, as well as the outcomes of children with MIS-C.
Method: Multicenter, prospective cohort study, conducted in 17 pediatric intensive care units in five states in Brazil, from March to July 2020. Patients from 1 month to 19 years who met the MIS-C diagnostic criteria were included consecutively.
Results: Fifty-six patients were included, with the following conditions: Kawasaki-like disease (n = 26), incomplete Kawasaki disease (n = 16), acute cardiac dysfunction (n = 10), toxic shock syndrome (n = 3), and macrophage activation syndrome (n = 1). Median age was 6.2 years (IQR 2.4-10.3), 70% were boys, 59% were non-whites, 20% had comorbidities, 48% reported a contact with COVID-19 cases, and 55% had a recent SARS-CoV-2 infection confirmed by RT-PCR and/or serology. Gastrointestinal symptoms were present in 71%, shock symptoms in 59%, and severe respiratory symptoms in less than 20%. d-Dimer was increased in 80% and cardiac dysfunction markers in more than 75%. Treatment included immunoglobulin (89%); corticosteroids, antibiotics, and enoxaparin in about 50%; and oseltamivir and antifungal therapy in less than 10%. Only 11% needed invasive mechanical ventilation, with a median duration of five days (IQR 5-6.5). The median length of PICU stay was six days (IQR 5-11), and one death occurred (1.8%).
Conclusions: Most characteristics of the present MIS-C patients were similar to that of other cohorts. The present results may contribute to a broader understanding of SARS-CoV-2 infection in children and its short-term consequences. Long-term multidisciplinary follow-up is needed, since it is not known whether these patients will have chronic cardiac impairment or other sequelae.

Keywords: COVID-19; Children; Coronavirus; MIS-C; Multisystem inflammatory syndrome in children; SARS-CoV-2.
 
Back
Top Bottom